scholarly journals Blood‑based microRNAs as diagnostic biomarkers to discriminate localized prostate cancer from benign prostatic hyperplasia and allow cancer‑risk stratification

2018 ◽  
Author(s):  
Ghada Al‑Kafaji ◽  
Harun Said ◽  
Mahmood Alam ◽  
Ziad Al Naieb
Keyword(s):  
Prostate Cancer ◽  
Benign Prostatic Hyperplasia ◽  
Cancer Risk ◽  
Risk Stratification ◽  
Prostatic Hyperplasia ◽  
Localized Prostate Cancer ◽  
Diagnostic Biomarkers

scholarly journals Genome-wide association study of germline copy number variations reveals an association with prostate cancer aggressiveness

Mutagenesis ◽  
2020 ◽  
Vol 35 (3) ◽  
pp. 283-290
Author(s):  
Stefanie Brezina ◽  
Moritz Feigl ◽  
Tanja Gumpenberger ◽  
Ricarda Staudinger ◽  
Andreas Baierl ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Benign Prostatic Hyperplasia ◽  
Risk Stratification ◽  
Cancer Patients ◽  
Copy Number ◽  
Copy Number Variations ◽  
Prostatic Hyperplasia ◽  
Aggressive Prostate Cancer ◽  
Genome Wide ◽  
Cancer Aggressiveness

Abstract Prostate cancer is a major health burden, being the second most commonly diagnosed malignancy in men worldwide. Overtreatment represents a major problem in prostate cancer therapy, leading to significant long-term quality-of-life effects for patients and a broad socio-ecological burden. Biomarkers that could facilitate risk stratification of prostate cancer aggressiveness at the time of diagnosis may help to guide clinical treatment decisions and reduce overtreatment. Previous research on genetic variations in prostate cancer has shown that germline copy number variations as well as somatic copy number alterations are commonly present in cancer patients, altering a greater portion of the cancer genome than any other type of genetic variation. To investigate the effect of germline copy number variations on cancer aggressiveness we have compared genome-wide screening data from genomic DNA isolated from the blood of 120 patients with aggressive prostate cancer, 231 patients with non-aggressive prostate cancer and 87 controls with benign prostatic hyperplasia from the Prostate Cancer Study of Austria biobank using the Affymetrix SNP 6.0 array. We could show that patients with an aggressive form of prostate cancer had a higher frequency of copy number variations [mean count of copy number segments (CNS) = 12.9, median count of CNS = 9] compared to patients with non-aggressive prostate cancer (mean count of CNS = 10.4, median count of CNS = 8) or control patients diagnosed with benign prostatic hyperplasia (mean count of CNS = 9.3, median count of CNS = 8). In general, we observed that copy number gain is a rarer event, compared to copy number loss within all three patient groups. Furthermore, we could show a significant effect of copy number losses located on chromosomes 8, 9 and 10 on prostate cancer aggressiveness (P = 0.040, P = 0.037 and P = 0.005, respectively). Applying a cross-validation analysis yielded an area under the curve of 0.63. Our study reports promising findings suggesting that copy number losses might play an important role in the establishment of novel biomarkers to predict prostate cancer aggressiveness at the time of diagnosis. Such markers could be used to facilitate risk stratification to reduce overtreatment of prostate cancer patients.

scholarly journals Synergistic interaction of benign prostatic hyperplasia and prostatitis on prostate cancer risk

2013 ◽  
Vol 108 (9) ◽  
pp. 1778-1783 ◽  
Author(s):  
S-C Hung ◽  
S-W Lai ◽  
P-Y Tsai ◽  
P-C Chen ◽  
H-C Wu ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Benign Prostatic Hyperplasia ◽  
Cancer Risk ◽  
Prostate Cancer Risk ◽  
Prostatic Hyperplasia ◽  
Synergistic Interaction
Sign in / Sign up

Export Citation Format

Share Document